+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Melanoma Drug Market by Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Mechanism Of Action (BRAF Inhibitors, Checkpoint Inhibitors, MEK Inhibitors), Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Melanoma Drug Market by Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Mechanism Of Action (BRAF Inhibitors, Checkpoint Inhibitors, MEK Inhibitors), Route Of Administration, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Melanoma Drug Market by Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), Mechanism Of Action (BRAF Inhibitors, Checkpoint Inhibitors, MEK Inhibitors), Route Of Administration, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 187 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968662
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Melanoma Drug Market grew from USD 5.81 billion in 2024 to USD 6.31 billion in 2025. It is expected to continue growing at a CAGR of 8.44%, reaching USD 9.46 billion by 2030.

Situating the melanoma drug ecosystem within evolving clinical, scientific, and regulatory dynamics to frame innovation imperatives and patient impact priorities

The landscape of melanoma therapeutics has experienced unprecedented change, propelled by breakthroughs in immunological understanding and advances in targeted molecular interventions. In recent years, the convergence of biologic agents and precision medicine has redefined treatment protocols, delivering new hope for improving survival and quality of life. Simultaneously, evolving regulatory frameworks have accelerated the pathway from bench to bedside, fostering an environment where innovation thrives under rigorous oversight.

This introduction establishes the foundational context for exploring these paradigm shifts. It highlights the interplay between scientific discovery, clinical trial design, and patient-centric outcomes that now drive strategic decision-making. By framing the critical drivers-ranging from novel biomarker identification to adaptive trial methodologies-this section sets the stage for a deeper examination of how emerging therapies are reshaping the global melanoma treatment ecosystem.

As research investment intensifies, stakeholders must navigate a complex mosaic of competitive dynamics, payer considerations, and evolving standard-of-care benchmarks. This synthesis underscores the importance of aligning research priorities with unmet clinical needs, ensuring that each innovation delivers tangible value for patients and healthcare systems alike.

Unveiling the paradigm shifts in melanoma therapy driven by immunotherapy breakthroughs and precision targeting strategies that redefine response outcomes

The melanoma treatment landscape is undergoing a profound metamorphosis characterized by the rise of immunotherapeutic agents that mobilize the patient’s own immune system against malignant cells. Breakthrough checkpoint inhibitors have quickly transitioned from experimental modalities into first-line therapies, setting new benchmarks for response durability. Concurrently, precision-targeted approaches are refining patient selection, leveraging genetic and molecular profiling to optimize treatment efficacy while minimizing collateral toxicity.

In parallel, the advent of combination regimens uniting immunotherapy with targeted inhibitors heralds a synergistic frontier. This evolution has compelled clinical researchers to redesign trial frameworks, incorporate adaptive protocols, and prioritize real-world evidence gathering. As a result, traditional single-agent paradigms are giving way to dynamic, iterative approaches that continuously integrate emerging data. Collectively, these transformative shifts underscore a new epoch in melanoma care, where scientific ingenuity and clinical agility coalesce to unlock unprecedented therapeutic potential.

Examining the ripple effects of 2025 US tariffs on raw material supply, clinical research logistics, pricing, and partnerships driving melanoma drug innovation

In 2025, the implementation of new United States tariffs has introduced a multifaceted ripple effect across the melanoma drug development continuum. Heightened duties on key raw materials have placed additional pressure on active pharmaceutical ingredient sourcing, prompting manufacturers to reassess supplier networks and explore regional alternatives. These constraints have, in turn, influenced production timelines, requiring greater logistical coordination and contingency planning to maintain pipeline momentum.

Clinical research activities have also felt the impact, as modifications in equipment and reagent costs necessitate recalibrated budget allocations. Trial sponsors are actively revising expenditure forecasts to accommodate these variable inputs, while regulatory submissions now frequently include tariff-related risk assessments. At the same time, international collaborations have taken on increased significance, with cross-border partnerships becoming essential for mitigating supply chain vulnerabilities and securing cost-effective solutions. Through this lens, the 2025 tariff landscape emerges as a critical determinant of both operational resilience and strategic positioning in melanoma drug innovation.

Decoding segmentation across therapy type, mechanism of action, administration route, and distribution channel to reveal insights in melanoma drug innovation

Decoding segmentation across therapy type, mechanism of action, administration route, and distribution channel reveals nuanced implications for pipeline prioritization and market access strategies. Within the category of therapy type, immunotherapy has rapidly emerged as a cornerstone, complemented by the foundational roles of chemotherapy and the expanding promise of targeted therapy. Looking closer at mechanisms of action highlights checkpoint inhibition as a game-changer-especially PD-1 and CTLA-4 blockade-while BRAF and MEK inhibitors continue to carve out precision niches for mutation-driven patient cohorts.

The debate between intravenous and oral administration routes underscores the evolving patient preference for convenience without compromising efficacy, prompting developers to balance formulation innovation with pharmacokinetic considerations. Meanwhile, the dual network of hospital pharmacies and retail pharmacies shapes distribution strategies, as each channel presents unique logistical and reimbursement nuances. Altogether, this layered segmentation framework empowers stakeholders to tailor development pathways, optimize access, and align resource allocation with the therapies and delivery models poised to deliver the greatest clinical and commercial impact.

Examining how policy shifts and evolving clinical access across Americas, EMEA and Asia Pacific are driving differentiated growth trajectories

Examining how policy shifts and evolving clinical access across Americas, EMEA and Asia Pacific are driving differentiated growth trajectories uncovers critical regional contrast. In the Americas, aggressive reimbursement models and robust clinical infrastructure accelerate the adoption of immunotherapies and novel targeted agents, supported by well-established oncology networks. Conversely, Europe, Middle East and Africa exhibit diverse regulatory landscapes, where harmonization efforts coalesce around central approval pathways but local pricing negotiations and reimbursement frameworks influence rollout cadence.

Asia Pacific demonstrates a rapidly expanding clinical trial footprint, driven by growing research collaborations and emerging center-of-excellence hubs. Patient access initiatives in this region are increasingly focused on bridging urban-rural divides and integrating oral therapies to enhance adherence. Across each geography, nuanced regulatory policy adaptations and payer strategies shape the speed and scale of new therapy introductions, compelling manufacturers to adopt region-specific engagement plans and distribution models that align with localized healthcare dynamics.

Profiling leading developers to understand competitive positioning, innovation pipelines, and collaborations shaping the melanoma drug landscape

Profiling leading developers reveals an ecosystem defined by intense innovation pipelines, strategic alliances, and competitive differentiation. Established pharmaceutical corporations leverage expansive R&D budgets to explore next-generation checkpoint modulators and bispecific antibodies, while emerging biotech firms focus on niche molecular targets and biomarker-driven trial designs. These dynamics have given rise to a collaborative ethos, with co-development agreements, academic partnerships, and real-world evidence platforms becoming standard vehicles for de-risking early-stage programs.

The competitive landscape is further shaped by cross-sector collaborations, where technology firms contribute advanced data analytics and digital health solutions to optimize patient stratification and monitor treatment outcomes. Licensing transactions and directed acquisitions underscore the high stakes of securing innovative assets, reflecting a market where first-mover advantage and intellectual property positioning are paramount. Together, these company-level insights spotlight the strategic imperatives and partnership models that will define success in the next wave of melanoma drug development.

Presenting recommendations for industry leaders to optimize research, streamline clinical trial processes, and foster innovation in melanoma drug discovery

To capitalize on emerging opportunities, industry leaders should first realign research portfolios toward combination regimens that integrate checkpoint inhibitors with targeted agents, thereby enhancing response durability and broadening patient applicability. Concurrently, sponsors must invest in adaptive trial methodologies and leverage digital biomarkers to streamline enrollment, reduce time to interim readouts, and generate compelling real-world evidence.

Second, forging strategic alliances with regional clinical centers and patient advocacy groups can accelerate market entry and support localized access programs. Collaborations that span supply chain stakeholders will also be essential for mitigating tariff-induced disruptions and optimizing production flexibility. Finally, embedding patient-centric insights throughout the development lifecycle-via decentralized trial components and digital health monitoring-will strengthen differentiation, bolster payer negotiations, and reinforce the value proposition for novel melanoma therapies.

Outlining the methodology based on primary expert interviews, secondary source assessment, and data validation to support insights into melanoma drug development

Outlining the methodology based on primary expert interviews, secondary source assessment, and data validation to support insights into melanoma drug development sets a rigorous analytical foundation. Primary interviews involved leading oncologists, regulatory specialists, and clinical trial coordinators who provided firsthand perspectives on emerging treatment paradigms, regulatory shifts, and operational challenges.

Secondary source assessment drew upon peer-reviewed literature, clinical registry databases, and policy documents to triangulate market trends and corroborate expert inputs. Data validation protocols included cross-referencing multiple independent sources, verifying historical trial outcomes, and stress-testing logistical assumptions against tariff and distribution variables. This integrated research approach ensures that the strategic recommendations and content insights accurately reflect the current state of melanoma therapy research and the multifaceted factors influencing development trajectories.

Drawing critical insights to underscore the imperative for innovation, collaboration, and adaptive strategies within the evolving melanoma drug landscape

Drawing critical insights to underscore the imperative for innovation, collaboration, and adaptive strategies within the evolving melanoma drug landscape crystallizes the strategic priorities ahead. The synthesis of segmentation, regional, tariff, and company-level analyses reveals a market in transition, where scientific breakthroughs converge with shifting policy frameworks and global supply challenges.

This conclusion reiterates the necessity for stakeholders to adopt an agile mindset-prioritizing flexible trial designs, dynamic partnerships, and patient-centric engagement-to navigate complexity and unlock therapeutic potential. Success in this environment will depend on integrating real-world evidence, harnessing data-driven insights, and sustaining cross-sector collaborations that propel the next frontier of melanoma care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Type
    • Chemotherapy
    • Immunotherapy
    • Targeted Therapy
  • Mechanism Of Action
    • BRAF Inhibitors
    • Checkpoint Inhibitors
      • CTLA-4 Inhibitors
      • PD-1 Inhibitors
    • MEK Inhibitors
  • Route Of Administration
    • Intravenous
    • Oral
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • AbbVie Inc.
  • GlaxoSmithKline PLC
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited
  • Hikma Pharmaceuticals PLC

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. The integration of combination immunotherapies to overcome checkpoint inhibitor resistance in advanced melanoma
5.2. Emergence of personalized neoantigen-based cancer vaccines targeting patient-specific melanoma mutations
5.3. Advancements in liquid biopsy assays enabling minimally invasive monitoring of melanoma progression and treatment response
5.4. Impact of teledermatology platforms and AI-driven image analysis on accelerating remote melanoma screening rates
5.5. Increasing adoption of PD-1/PD-L1 bispecific antibodies providing dual checkpoint blockade in melanoma therapy pipelines
5.6. Development of sequential BRAF and MEK inhibitor regimens to prolong response durability in BRAF-mutant melanoma patients
5.7. Exploration of gut microbiome modulation strategies to improve clinical outcomes in melanoma immunotherapy combinations
5.8. Growing interest in oncolytic virus therapies extending treatment options for refractory and advanced-stage melanoma cases
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Melanoma Drug Market, by Therapy Type
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.4. Targeted Therapy
9. Melanoma Drug Market, by Mechanism Of Action
9.1. Introduction
9.2. BRAF Inhibitors
9.3. Checkpoint Inhibitors
9.3.1. CTLA-4 Inhibitors
9.3.2. PD-1 Inhibitors
9.4. MEK Inhibitors
10. Melanoma Drug Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
11. Melanoma Drug Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Retail Pharmacies
12. Americas Melanoma Drug Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Melanoma Drug Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Melanoma Drug Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AbbVie Inc.
15.3.2. GlaxoSmithKline PLC
15.3.3. Merck KGaA
15.3.4. F. Hoffmann-La Roche Ltd.
15.3.5. Novartis AG
15.3.6. Regeneron Pharmaceuticals Inc.
15.3.7. Eli Lilly and Company
15.3.8. Pfizer, Inc.
15.3.9. Takeda Pharmaceutical Company Limited
15.3.10. Hikma Pharmaceuticals PLC
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. MELANOMA DRUG MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. MELANOMA DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. MELANOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. MELANOMA DRUG MARKET: RESEARCHAI
FIGURE 24. MELANOMA DRUG MARKET: RESEARCHSTATISTICS
FIGURE 25. MELANOMA DRUG MARKET: RESEARCHCONTACTS
FIGURE 26. MELANOMA DRUG MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MELANOMA DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MELANOMA DRUG MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MELANOMA DRUG MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MELANOMA DRUG MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MELANOMA DRUG MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MELANOMA DRUG MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MELANOMA DRUG MARKET SIZE, BY BRAF INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MELANOMA DRUG MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MELANOMA DRUG MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MELANOMA DRUG MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MELANOMA DRUG MARKET SIZE, BY MEK INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MELANOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MELANOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MELANOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MELANOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MELANOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MELANOMA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. AMERICAS MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 44. AMERICAS MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES MELANOMA DRUG MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 67. CANADA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 68. CANADA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 69. CANADA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 70. CANADA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 71. CANADA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 72. CANADA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 73. CANADA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. CANADA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. CANADA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. MEXICO MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 78. MEXICO MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 79. MEXICO MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 80. MEXICO MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 81. MEXICO MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 82. MEXICO MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 83. MEXICO MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 84. MEXICO MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 85. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. MEXICO MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. BRAZIL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 88. BRAZIL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. ARGENTINA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 98. ARGENTINA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 119. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 120. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. GERMANY MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 130. GERMANY MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 131. GERMANY MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 132. GERMANY MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 133. GERMANY MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 134. GERMANY MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 135. GERMANY MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. GERMANY MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. GERMANY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. GERMANY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. FRANCE MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 140. FRANCE MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 141. FRANCE MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 142. FRANCE MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 143. FRANCE MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 144. FRANCE MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 145. FRANCE MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. FRANCE MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. FRANCE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. FRANCE MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. RUSSIA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 150. RUSSIA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. ITALY MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 160. ITALY MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 161. ITALY MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 162. ITALY MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 163. ITALY MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 164. ITALY MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 165. ITALY MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. ITALY MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. ITALY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. ITALY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. SPAIN MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 170. SPAIN MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 171. SPAIN MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 172. SPAIN MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 173. SPAIN MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 174. SPAIN MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 175. SPAIN MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 176. SPAIN MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 177. SPAIN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. SPAIN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 190. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 200. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. DENMARK MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 210. DENMARK MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 211. DENMARK MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 212. DENMARK MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 213. DENMARK MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 214. DENMARK MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 215. DENMARK MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 216. DENMARK MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 217. DENMARK MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. DENMARK MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 220. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. QATAR MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 230. QATAR MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 231. QATAR MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 232. QATAR MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 233. QATAR MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 234. QATAR MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 235. QATAR MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. QATAR MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. QATAR MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. QATAR MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. FINLAND MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 240. FINLAND MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 241. FINLAND MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 242. FINLAND MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 243. FINLAND MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 244. FINLAND MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 245. FINLAND MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. FINLAND MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. FINLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. FINLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. SWEDEN MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 250. SWEDEN MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. NIGERIA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 260. NIGERIA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 269. EGYPT MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 270. EGYPT MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 271. EGYPT MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 272. EGYPT MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 273. EGYPT MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. EGYPT MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. EGYPT MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. EGYPT MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. EGYPT MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. EGYPT MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. TURKEY MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 280. TURKEY MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 281. TURKEY MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 282. TURKEY MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 283. TURKEY MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 284. TURKEY MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 285. TURKEY MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. TURKEY MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. TURKEY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. TURKEY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. ISRAEL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 290. ISRAEL MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 291. ISRAEL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 292. ISRAEL MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 296. ISRAEL MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. NORWAY MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 300. NORWAY MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 301. NORWAY MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 302. NORWAY MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 303. NORWAY MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 304. NORWAY MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 305. NORWAY MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. NORWAY MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. NORWAY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. NORWAY MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. POLAND MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 310. POLAND MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 311. POLAND MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 312. POLAND MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 313. POLAND MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 314. POLAND MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 315. POLAND MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 316. POLAND MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 317. POLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. POLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 320. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 321. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 322. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 323. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 324. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 325. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 328. SWITZERLAND MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 329. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 330. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 332. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 334. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 335. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 336. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 337. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 338. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 339. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 340. ASIA-PACIFIC MELANOMA DRUG MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 341. CHINA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 342. CHINA MELANOMA DRUG MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 343. CHINA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
TABLE 344. CHINA MELANOMA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
TABLE 345. CHINA MELANOMA DRUG MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie Inc.
  • GlaxoSmithKline PLC
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Eli Lilly and Company
  • Pfizer, Inc.
  • Takeda Pharmaceutical Company Limited
  • Hikma Pharmaceuticals PLC

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.31 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.46 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Melanoma Therapeutics Market Report 2025 - Product Image

Melanoma Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Melanoma Drugs Market Report 2025 - Product Image

Melanoma Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Melanoma Therapeutics - Global Strategic Business Report - Product Image

Melanoma Therapeutics - Global Strategic Business Report

  • Report
  • 162 Pages
  • Global
From
Unresectable Melanoma Drug Pipeline Analysis Report 2025 - Product Image

Unresectable Melanoma Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Unresectable Melanoma - Pipeline Insight, 2025 - Product Image

Unresectable Melanoma - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From

About the Melanoma Drug Market

The Melanoma Drug market is a subset of the larger Skin Cancer Drugs market. It is composed of drugs used to treat melanoma, a type of skin cancer. These drugs are typically used in combination with other treatments such as surgery, radiation, and immunotherapy. Commonly used drugs include targeted therapies, immunotherapies, and chemotherapy. Targeted therapies are designed to target specific molecules in the cancer cells, while immunotherapies are designed to boost the body's own immune system to fight the cancer. Chemotherapy is used to kill cancer cells. The Melanoma Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Bristol-Myers Squibb, Merck, Roche, Novartis, and Pfizer. Other companies include AstraZeneca, Eli Lilly, and GlaxoSmithKline. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.